The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer.
L. A. Emens
Consultant or Advisory Role - Genentech
Research Funding - Genentech
R. Gupta
No relevant relationships to disclose
S. Petrik
No relevant relationships to disclose
M. Laiko
No relevant relationships to disclose
J. M. Leatherman
No relevant relationships to disclose
J. Levi
No relevant relationships to disclose
J. M. Asquith
No relevant relationships to disclose
M. M. Daphtary
No relevant relationships to disclose
E. Garrett-Mayer
No relevant relationships to disclose
B. J. Kobrin
No relevant relationships to disclose
N. E. Davidson
No relevant relationships to disclose
T. Dauses
No relevant relationships to disclose
S. Atay-Rosenthal
No relevant relationships to disclose
X. Ye
No relevant relationships to disclose
A. C. Wolff
Research Funding - Genentech
V. Stearns
Research Funding - Abraxis BioScience; Merck; Novartis; Pfizer
E. M. Jaffee
Consultant or Advisory Role - Amplimmune; Pfizer
Research Funding - Pfizer